These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 3113727)

  • 1. Effects of various oxygenation conditions on the enhancement by Fluosol-DA of melphalan antitumor activity.
    Teicher BA; Crawford JM; Holden SA; Cathcart KN
    Cancer Res; 1987 Oct; 47(19):5036-41. PubMed ID: 3113727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity.
    Teicher BA; Holden SA; Jacobs JL
    Cancer Res; 1987 Jan; 47(2):513-8. PubMed ID: 3098413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
    Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of oxygen on the cytotoxicity and antitumor activity of etoposide.
    Teicher BA; Holden SA; Rose CM
    J Natl Cancer Inst; 1985 Dec; 75(6):1129-33. PubMed ID: 3934448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo.
    Teicher BA; Herman TS; Holden SA; Cathcart KN
    Cancer Chemother Pharmacol; 1988; 21(4):286-91. PubMed ID: 3131033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential enhancement of melphalan cytotoxicity in tumor and normal tissue by Fluosol-DA and oxygen breathing.
    Teicher BA; Holden SA; Rose CM
    Int J Cancer; 1985 Nov; 36(5):585-9. PubMed ID: 3932225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survey of the effect of adding Fluosol-DA 20%/O2 to treatment with various chemotherapeutic agents.
    Teicher BA; Holden SA
    Cancer Treat Rep; 1987 Feb; 71(2):173-7. PubMed ID: 3100035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of various oxygenation conditions and fluosol-DA on cytotoxicity and antitumor activity of bleomycin in mice.
    Teicher BA; Holden SA; Cathcart KN; Herman TS
    J Natl Cancer Inst; 1988 Jun; 80(8):599-603. PubMed ID: 2453675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.
    Teicher BA; Bernal SD; Holden SA; Cathcart KN
    Cancer Chemother Pharmacol; 1988; 21(4):281-5. PubMed ID: 3131032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of photodynamic therapy-induced hypoxia by fluosol-DA (20%) and carbogen breathing in mice.
    Fingar VH; Mang TS; Henderson BW
    Cancer Res; 1988 Jun; 48(12):3350-4. PubMed ID: 3130983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for macrophage involvement in the enhancement of tumor growth delay with X-ray/Fluosol-DAR/O2 combination therapy.
    Holden SA; Teicher BA; McIntosh NL; Rose CM
    Anticancer Res; 1987; 7(3 Pt B):385-90. PubMed ID: 3115174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma.
    Teicher BA; Holden SA; al-Achi A; Herman TS
    Cancer Res; 1990 Jun; 50(11):3339-44. PubMed ID: 2334928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of tumor oxygenation after cytotoxic therapy by a perflubron emulsion/carbogen breathing.
    Teicher BA; Holden SA; Ara G; Dupuis NP; Goff D
    Cancer J Sci Am; 1995; 1(1):43-8. PubMed ID: 9166453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of a hypoxic cell selective cytotoxic agent (mitomycin C or porfiromycin) to Fluosol-DA/carbogen/radiation.
    Holden SA; Herman TS; Teicher BA
    Radiother Oncol; 1990 May; 18(1):59-70. PubMed ID: 2113698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of Fluosol-DA on the occurrence of lung metastases in Lewis lung carcinoma and B16 melanoma.
    Teicher BA; Jacobs JL; Kelley MJ
    Invasion Metastasis; 1988; 8(1):45-56. PubMed ID: 3343092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.
    Teicher BA; Herman TS; Tanaka J; Dezube B; Pardee A; Frei E
    Cancer Chemother Pharmacol; 1991; 28(1):45-50. PubMed ID: 1904012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N',N''-triethylenethiophosphoramide.
    Teicher BA; Waxman DJ; Holden SA; Wang YY; Clarke L; Alvarez Sotomayor E; Jones SM; Frei E
    Cancer Res; 1989 Sep; 49(18):4996-5001. PubMed ID: 2504483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Fluosol-DA/O2 on tumor-cell and bone-marrow cytotoxicity of nitrosoureas in mice bearing FSA-II fibrosarcoma.
    Teicher BA; Holden SA; Rose CM
    Int J Cancer; 1986 Aug; 38(2):285-8. PubMed ID: 3089945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a perfluorochemical emulsion on the response of BA1112 rat rhabdomyosarcomas to continuous low-dose-rate irradiation.
    Morton JD; Porter E; Yabuki H; Nath R; Rockwell S
    Radiat Res; 1990 Nov; 124(2):178-82. PubMed ID: 2123353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
    Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.